OptiBiotix Benefitting From Popularity Of Anti-Obesity Drugs

Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.

magnifying glass over GLP-1 written on scrap of paper. other paper scraps read "obesity," "semaglutide" "weight loss"

The growing popularity of anti-obesity drugs like Wegovy (semaglutide) is having a positive effect on the market for weight loss supplements, according to OptiBiotix Health.

More from Earnings

More from Strategy

OptiBiotix Benefitting From Popularity Of Anti-Obesity Drugs

 
• By 

Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.

Schwabe Taps Into Younger Audience With Braineffect Deal

 
• By 

By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.

People On The Move: Appointments At GSCF, Kenvue, Barentz

 
• By 

A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.